BioSpace News Archive

Increasing implementation of newborn screening programs mandated by governments, extensive R&D to develop advanced products, and surge in neonatal diseases and disorders are key factors driving market growth.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), announced today that it will be presenting virtually this week at the 28th International Biodetection Technologies Conference as well as hosting a virtual booth at the 65th Annual CARPHA Health Research Conference.

Hyperfine, Inc., creators of the world’s first portable magnetic resonance imaging device, has named Scott Huennekens Executive Chairman of the Board.

BioProtect Ltd., a private commercial-stage medical device company, announced today that the company has enrolled all the planned patients in the ongoing IDE ProSpace™ trial, with a total of 222 patients recruited and randomized.

A U.S. clinical trial of a COVID-19 rapid test approved by an institutional review board found the Specificity of confirmed negative Covid-19 patients by RT-PCR was 100% (95% CI, 88.4%-100.0%); meaning there was 100% agreement between a negative RT-PCR and negative Clungene® serological test result.

Nineteen percent of COVID-19 patients without symptoms went on to exhibit at least one of the post-COVID conditions known as long-haul COVID 30 days or more after their initial COVID-19 diagnosis.1 This is among the findings in FAIR Health’s new white paper, the eighth of its COVID-19 studies, A Detailed Study of Patients with Long-Haul COVID: An Analysis of Private Healthcare Claims.

PulmoSIM Therapeutics (PulmoSIM), the pharmaceutical subsidiary of VeriSIM Life, Inc., is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for asset PT001 for the treatment of Pulmonary Arterial Hypertension (PAH).

JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB)

Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Banyan Software, Inc., is pleased to announce the acquisition of HealthRx Corporation, a company that provides research workflow, lab safety and occupational health management software solutions through its integrated Nexus platform